Apellis Pharmaceuticals, a biotech focused on complement-mediated diseasesgurufocus.com, delivered standout financial results for the third quarter of 2025 – yet its stock took a beating. The company reported Q3 revenue of $458.6 million, more than doubling from $196.8 M in the same quarter last yearinvesting.com. This record top-line was boosted by a one-time $275 M licensing deal with partner Sobiinvesting.com, which paid Apellis upfront for future ex-U.S. royalties on Aspaveli. Thanks largely to this deal, Apellis swung to a net profit of $215.7 Mmarkets.businessinsider.com.
